Reuters -- U.S. health officials on Thursday said they found no increased risk of heart trouble with use of Pfizer Inc's (PFE.N) inhaled lung drug Spiriva. The U.S. Food and Drug Administration, in a statement, said it had finished reviewing data for the chronic obstructive pulmonary disease (COPD) treatment and did not find a higher chance of stroke, heart attack or death with the drug.
